The factory of the future: Will cell therapy manufacturing be replaced, reinvented, or brought to the patient?
04 Nov 2026
Cell Therapy Manufacturing
- The Future of Ex Vivo Manufacturing: Evolution or Extinction
With advances in in vivo CAR engineering, allogeneic platforms, and gene delivery
technologies, are we witnessing the beginning of the end for traditional ex vivo
autologous cell therapy manufacturing — or the next phase of its evolution? - Manufacturing Accessibility: Is Centralized Manufacturing the Bottleneck?
If CAR T Can deliver durable responses, but only a fraction of eligible patients receive
therapy, do we have a science problem, a manufacturing problem or a business
problem? - Point of Care Manufacturing: Revolutionary or Regulatory Nightmare?
Can decentralized manufacturing deliver the same GMP consistency as centralized
manufacturing OR are we trading speed for control? - Automation, Closed Systems & AI: Removing Variability or Removing Expertise?
As platforms become increasingly automated, are we reducing manufacturing risk OR
creating new risks we do not fully understand yet? - Quality Control of the Future: Are Traditional Release Tests Still Fit-for-Purpose?
Can the QC approaches that support Ex Vivo Cell Therapy Manufacturing support the In
Vivo Cell Therapy paradigm? - From Hero Manufacturing to Industrialized Manufacturing:
Early cell therapy success was built by scientific heroes solving difficult problems. To
reach all eligible patients, do we need fewer heroes and stronger systems? - The next 5 years: What Will Define the Winners?
Given the fast progression of advanced therapies, five years from now, what will define
successful cell therapy organizations from those that disappear?